Free Trial

Tenaya Therapeutics (TNYA) Competitors

Tenaya Therapeutics logo
$0.84 -0.02 (-2.74%)
As of 12:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TNYA vs. ARVN, SEPN, PHAT, TSHA, VALN, PGEN, RAPP, OPT, ORKA, and ATYR

Should you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include Arvinas (ARVN), Septerna (SEPN), Phathom Pharmaceuticals (PHAT), Taysha Gene Therapies (TSHA), Valneva (VALN), Precigen (PGEN), Rapport Therapeutics (RAPP), Opthea (OPT), Oruka Therapeutics (ORKA), and aTyr Pharma (ATYR). These companies are all part of the "pharmaceutical products" industry.

Tenaya Therapeutics vs. Its Competitors

Arvinas (NASDAQ:ARVN) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Arvinas has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 3, suggesting that its share price is 200% more volatile than the S&P 500.

Tenaya Therapeutics has a net margin of 0.00% compared to Arvinas' net margin of -10.92%. Arvinas' return on equity of -7.74% beat Tenaya Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arvinas-10.92% -7.74% -4.11%
Tenaya Therapeutics N/A -92.20%-74.53%

Tenaya Therapeutics has lower revenue, but higher earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arvinas$263.40M2.17-$198.90M-$0.66-11.89
Tenaya TherapeuticsN/AN/A-$111.13M-$1.16-0.73

Arvinas currently has a consensus price target of $20.29, suggesting a potential upside of 158.63%. Tenaya Therapeutics has a consensus price target of $6.25, suggesting a potential upside of 642.28%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than Arvinas.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arvinas
0 Sell rating(s)
10 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.55
Tenaya Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

95.2% of Arvinas shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 4.7% of Arvinas shares are held by insiders. Comparatively, 48.7% of Tenaya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Arvinas had 3 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 4 mentions for Arvinas and 1 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 1.87 beat Arvinas' score of 0.53 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Arvinas Positive
Tenaya Therapeutics Very Positive

Summary

Tenaya Therapeutics beats Arvinas on 8 of the 15 factors compared between the two stocks.

Get Tenaya Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TNYA vs. The Competition

MetricTenaya TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$136.81M$3.02B$5.70B$9.51B
Dividend YieldN/A2.40%4.60%3.99%
P/E Ratio-0.7320.9027.9419.99
Price / SalesN/A332.33456.59102.06
Price / CashN/A43.2336.5558.97
Price / Book0.798.228.585.86
Net Income-$111.13M-$55.19M$3.24B$258.50M
7 Day Performance-4.00%5.21%3.67%1.89%
1 Month Performance22.03%16.91%10.24%12.18%
1 Year Performance-78.90%4.19%34.02%18.94%

Tenaya Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TNYA
Tenaya Therapeutics
3.82 of 5 stars
$0.84
-2.7%
$6.25
+642.3%
-77.2%$136.81MN/A-0.73110Positive News
ARVN
Arvinas
4.0032 of 5 stars
$7.52
+2.3%
$20.29
+169.8%
-72.7%$548.89M$263.40M-11.39420News Coverage
Upcoming Earnings
SEPN
Septerna
1.8392 of 5 stars
$12.31
-1.9%
$26.75
+117.3%
N/A$548.53M$1.08M0.00N/APositive News
PHAT
Phathom Pharmaceuticals
4.3157 of 5 stars
$7.83
-1.5%
$17.50
+123.5%
-21.0%$546.61M$55.25M-1.49110Positive News
TSHA
Taysha Gene Therapies
4.2417 of 5 stars
$2.53
-1.6%
$8.17
+222.8%
+15.6%$543.09M$8.33M-7.44180
VALN
Valneva
1.9705 of 5 stars
$6.35
-3.1%
$15.50
+144.1%
+5.9%$540.32M$183.52M-5.34700News Coverage
Gap Up
PGEN
Precigen
3.9342 of 5 stars
$1.83
+4.0%
$6.00
+227.9%
-2.1%$540.18M$4.20M-3.27190Positive News
RAPP
Rapport Therapeutics
1.5469 of 5 stars
$14.39
-2.0%
$28.00
+94.6%
-17.8%$525.24MN/A-4.17N/A
OPT
Opthea
0.3953 of 5 stars
$3.41
+7.2%
$1.33
-60.9%
+50.9%$524.83M$120K0.008Gap Up
ORKA
Oruka Therapeutics
2.7117 of 5 stars
$13.77
-5.3%
$40.38
+193.2%
N/A$515.55MN/A-3.05N/AUpcoming Earnings
Analyst Forecast
ATYR
aTyr Pharma
2.1851 of 5 stars
$5.71
-4.7%
$20.20
+253.8%
+187.6%$508.19M$230K-7.0553Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:TNYA) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners